Objectives We aimed to perform a gender‐based meta‐analysis of the outcome of
bivalirudin versus heparin in patients undergoing percutaneous coronary interventions …

Background Bivalirudin has been shown to be associated with less major bleeding than
heparin in patients undergoing percutaneous coronary intervention (PCI); but the …

Background: Bivalirudin reduces ischemic and hemorrhagic events in patients undergoing
primary percutaneous coronary intervention (PCI), but the safety and efficacy for such …

Bivalirudin has been shown to be safe and efficacious compared with heparin plus
glycoprotein IIb/IIIa inhibitor (GPI) in patients undergoing percutaneous coronary …

Background The anticoagulant of choice during percutaneous coronary intervention (PCI) in
women is not well established. Methods An electronic search was conducted for trials that …

Background Bivalirudin is an alternative to heparin in patients undergoing percutaneous
coronary intervention (PCI). We aimed to define the effects of a bivalirudin-based …

Bivalirudin has gained ground against unfractionated heparin (UFH) in percutaneous
coronary interventions (PCI), due to a reported better safety profile. However, whether …

Background Bivalirudin significantly reduces 30-day major and minor bleeding compared
with unfractionated heparin (UFH), while resulting in similar or lower rates of ischemic …

OBJECTIVE: This meta-analysis was performed to assess the efficacy and safety of
bivalirudin compared with unfractionated heparin or enoxaparin plus glycoprotein (GP) …

Background: This meta-analysis is to evaluate the efficacy and safety of bivalirudin in
patients with ST-elevation myocardial infarction (STEMI). Methods: PubMed, Cochrane …